Clinical Trial Update: A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial of JNJ-39758979 in patients with active rheumatoid arthritis on methotrexate has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• JNJ-39758979

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Active Rheumatoid Arthritis; Rheumatoid Arthritis | Phase 2 | Status: WITHDRAWN